The combination of anti-DLL4 and gemcitabine had additive antitumor activity in pancreatic cancer xenograft models and delayed tumor recurrence after termination of gemcitabine treatment targeting DLL4 both in tumor and in stroma/vasculature [582]. Here, DLL4 is linked to familial pancreatic carcinoma.